Onconetix, Inc. (ONCO) Form 10-Q — Aug 13, 2026
Onconetix filed its 10-Q for the quarter ended June 30, 2026, reporting revenue of just $17,120, down from $106,494 a year earlier, with a quarterly net loss of $2.87 million and a first-half net loss of $7.08 million that included an $8.6 million goodwill impairment. The company disclosed substantial doubt about its ability to continue as a going concern, which management's plans do not alleviate. It held $5.9 million in cash at June 30, 2026, used roughly $4.0 million of cash in operations during the first half, and carried an accumulated deficit of $138.3 million. Onconetix executed two reverse stock splits in 2026 — 1-for-5 in March and 1-for-10 in May — as its stock declined.
Key figures
- Revenue
- 17120
- Revenue Yoy
- -84% (Q2 2026 vs Q2 2025, computed from stated figures of $17,120 vs $106,494)
- Cash Position
- 5942249
- Shares Outstanding
- 3949107
- Accumulated deficit
- 138296736
- Eloc commitment fee
- 30000000
- Series f pipe shares
- 37812
- Warrants outstanding
- 24212655
- Notes payable current
- 150394
- Reverse split may 2026
- 1:10
- July 2026 eloc capacity
- $750,000,000 or 19.99% of shares outstanding, whichever is less
- Revenue six months 2025
- 208124
- Revenue six months 2026
- 38577
- Working capital surplus
- 3600000
- Reverse split march 2026
- 1:5
- Total stockholders equity
- 13468509
- Cash august 10 2026 approx
- 5400000
- Series f net cash proceeds
- 249600
- Goodwill impairment q2 2026
- 486000
- Series f pipe purchase price
- 30249600
- Goodwill impairment six months 2026
- 8620000
- Warrant weighted avg exercise price
- 1.27
- Realbotix net cash closing condition
- 12500000
- Series d conversion shares available
- 15325066
- Total potentially dilutive securities
- 39537759
Price after filing
Close on the filing date to close N calendar days later (from $0.97). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.